INVESTOR NEWS no. 29 – 8 October 2026
 

DFDS’ agreement to acquire Naviera Armas’ Strait of Gibraltar ferry operations on Algeciras-Tangier Med has been approved by the Spanish and Moroccan competition authorities.

The transaction includes one combined freight and passenger ferry (RoPax) deployed on Algeciras-Tangier Med. Permits related to route operations are also included and around 200 employees will transfer to DFDS. The total purchase price for the Algeciras-Tangier Med route assets is DKK 165m. The transaction was completed today.

The route will be merged with DFDS’ existing ferry route on Strait of Gibraltar between Algeciras and Tangier Med. This will expand and enhance DFDS’ customer offering to both freight customers and passengers and add scale to operations in a growing market.

The purchased ferry is Volcan de Tamasite (RoPax) built in 2004. In addition, the capacity share is increased from 33% to 50% on a joint freight ferry (RoRo) for the incumbent operators on Algeciras-Tangier Med.

DFDS will not acquire Algeciras-Ceuta
DFDS’ agreement to acquire Naviera Armas’ Strait of Gibraltar ferry operations on Algeciras-Ceuta was conditional on the degree of competition authority restrictions. As the Spanish competition authority’s requirements went beyond the agreed conditions, DFDS has decided not to proceed with this agreement.

Capex outlook adjusted
DFDS’ 2026 full-year capex outlook is maintained unchanged at DKK 1.7bn as the added acquisition capex of DKK 165m is expected to be offset by lower than expected operating capex. The Adjusted free cash flow outlook is unchanged as acquisition capex is not reported as part of the Adjusted free cash flow.

Contact

Søren Brøndholt Nielsen, IR +45 33 42 33 59
Dennis Kjærsgaard, Media +45 42 30 38 47

About DFDS

We operate a transport network in and around Europe with an annual revenue of DKK 32bn and 15,000 full-time employees.

We move goods in trailers by ferry, road & rail, and we offer complementary transport and logistics solutions.

We also move car and foot passengers on short sea and overnight ferry routes.

DFDS was founded in 1866 and headquartered and listed in Copenhagen.

Attachment

WISeSat.Space and FOSSA Systems Confirm October 2026 Satellite Launch, Advancing the QSOC Constellation Roadmap

New mission builds on four years of collaboration to integrate post-quantum security, hardware roots of trust and digital identity into hardened satellite platforms.

Geneva, Switzerland / Madrid, Spain — October 8, 2026 — WISeSat.Space Holdings Corp., Nasdaq: SAIQ) (“WISeSat”), a space technology company and FOSSA Systems today confirmed a new satellite launch scheduled for October 2026. The mission will mark the beginning of a new series of launches into orbit that will support the progressive development of QSOC, the Quantum Spatial Orbital Cloud, and its vision for decentralized, quantum-resilient and sovereign space infrastructure.

The announcement builds on four years of cooperation between the companies, including WISeSat’s investment in FOSSA Systems. This collaboration supports the integration of post-quantum security, hardware roots of trust and digital identity into hardened satellite platforms, combining FOSSA’s satellite engineering and operations capabilities with WISeSat’s secure space infrastructure strategy.
Alongside the announcement, the companies are unveiling a first look at images captured from orbit by a WISeSat spacecraft, including a view taken over the WISeSat.Space headquarters.

    
Image taken by a WISeSat spacecraft over the WISeSat.Space headquarters, shown without (left) and with (right) the country outline.

Extending trust across satellites, ground infrastructure and user endpoints

QSOC is designed to bring the space infrastructure itself inside the trusted security perimeter. Its architecture combines hardware protection, authenticated digital identities, quantum-resilient cryptography and secure key management with high-performance symmetric encryption.
Hardware roots of trust are intended to protect cryptographic keys and support verification of devices and software. Digital identities enable authentication of satellites, ground stations and connected endpoints, while post-quantum cryptography strengthens the roadmap for key establishment and digital signatures against future quantum computing threats.

These technologies will be introduced progressively through successive missions, testing and integration milestones, building an end-to-end trust architecture capable of evolving throughout the constellation’s operational life.

Enabling sovereign hybrid constellations

The launch series will support a modular constellation architecture, allowing additional satellites, security capabilities and services to be incorporated over time.

QSOC is intended to enable hybrid constellations combining dedicated WISeSat satellites, compatible partner-operated space assets and terrestrial networks within a common trust framework. This approach aims to give governments, enterprises and critical infrastructure operators greater control over digital identities, cryptographic keys, data access and service governance.

The long-term objective is to establish decentralized orbital infrastructure supporting secure IoT connectivity, trusted data exchange and resilient communications for sovereign and commercial applications.

Carlos Moreira, Founder and CEO of WISeSat.Space, noted, “Over the past four years, our collaboration with FOSSA Systems has helped establish the foundations for trusted space infrastructure. The October launch marks the next step in our QSOC roadmap, progressively bringing post-quantum security, hardware roots of trust and digital identity into orbit. Our ambition is to enable sovereign hybrid constellations where trust extends from the satellite to the ground infrastructure and every connected endpoint.”

About FOSSA Systems

FOSSA Systems is a Spain-based aerospace company specializing in small-satellite development, launch and operations, providing space infrastructure for communications and related applications. Visit fossa.systems.

About WISeSat.Space
WISeSat.Space Holdings Corp. (NASDAQ: SAIQ) is a space technology company focused on secure satellite communications and related space infrastructure. Its approach combines satellite infrastructure with cybersecurity and digital identity technologies to support trusted communications between connected devices and ground-based systems. WISeSat.Space intends to provide satellite capacity and related space and ground infrastructure that may support SEALSQ’s planned QSOC roadmap. Visit wisesat.space⁠.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding estimation of the listing. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of WISeSat’s management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although WISeSat believes that it has a reasonable basis for each forward-looking statement contained in this press release, WISeSat cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of WISeSat as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, WISeSat does not undertake any duty to update these forward-looking statements.

CONTACTS

WISeSat:
Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
info@wisesat.com

WISeSat Investor Relations:
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
Lena.cati@theequitygroup.com

Approximately $28 million in planned TRUKING equipment advances domestic manufacturing capacity, strengthens the Company’s preparedness strategy, and supports new commercial opportunities

SPRING BRANCH, Texas, Oct. 08, 2026 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified preparedness, logistics, and critical-infrastructure company, today announced progress toward establishing domestic pharmaceutical manufacturing at the Atlas Complex in Marion, Alabama, through an equipment procurement and distribution collaboration with TRUKING. The Company has signed an initial purchase order and expects to make a $500,000 down payment toward approximately $28 million in pharmaceutical manufacturing equipment planned for installation at Atlas.

The collaboration also provides for Callan JMB to serve as a North American distributor and assembly provider for TRUKING equipment. This role extends the Company’s participation beyond the initial Atlas deployment to equipment distribution and assembly for additional planned pharmaceutical manufacturing sites and other commercial customers.

The initiative builds on Callan JMB’s longstanding emergency-preparedness and response work by connecting planned domestic pharmaceutical production with the logistics, regulatory compliance, specialty packaging, warehousing, monitoring, and distribution capabilities used to protect and deliver critical supplies. Bringing these functions together at the Atlas Complex in Marion, Alabama is intended to support continuity of supply during routine operations and periods of heightened demand or disruption. Equipment distribution and assembly would also broaden the Company’s commercial participation in the infrastructure supporting pharmaceutical manufacturing.

“Our work in preparedness and response has always depended on knowing how to source critical products, protect their integrity, and get them where they are needed,” said Wayne Williams, Chief Executive Officer of Callan JMB. “Developing pharmaceutical manufacturing at the Atlas Complex extends that experience further into the supply chain. By connecting U.S. production with our logistics and distribution capabilities, we aim to strengthen the availability of essential products before an emergency and support resupply when demand increases. Our role with TRUKING also creates an opportunity to support additional manufacturing projects and commercial customers.”

The initial equipment deployment is being coordinated with development of the planned 90,000-square-foot Marion 9 manufacturing facility at the Atlas Complex. The facility is intended to support U.S. production of pharmaceutical products affected by critical supply shortages, with equipment fabrication and facility construction expected to proceed in parallel.

TRUKING is an international supplier of pharmaceutical equipment and integrated manufacturing solutions. The collaboration brings its specialized equipment capabilities into a U.S. manufacturing project, with equipment specifications being developed at the Atlas Complex facility. TRUKING will fabricate the equipment at its facilities in China, then ship it to Alabama for Callan JMB to assemble and install. The planned pharmaceutical production will take place at the Atlas Complex, supporting the initiative’s objective of expanding domestic manufacturing capacity.

Callan JMB plans to establish a dedicated assembly team to support the Atlas Complex installation and subsequent equipment deployments. Company teams are expected to participate in pre-shipment testing and qualification activities and support installation, qualification, and validation at Atlas in preparation for manufacturing operations.

Management currently anticipates approximately nine months for equipment fabrication and six to nine months for facility construction. Initial production is targeted before the end of 2027, subject to completion of construction, equipment delivery and installation, commissioning, validation, and applicable regulatory requirements.

The planned production model combines active pharmaceutical ingredients expected to be supplied by Walker’s Pharmaceuticals with fill-finish capabilities at the Atlas Complex. Callan JMB’s supporting services are intended to connect those manufacturing activities with the storage, packaging, handling, and distribution required to deliver finished products to healthcare and commercial customers.

About Callan JMB Inc.

Callan JMB Inc. (NASDAQ: CJMB) is a diversified logistics, preparedness, and critical-infrastructure company supporting healthcare organizations, government agencies, and commercial partners. The Company provides fulfillment, warehousing, cold-chain logistics, monitoring, regulatory compliance, specialty packaging, and emergency-preparedness and response services designed to protect critical products, strengthen supply chains, and support continuity of operations. Through its portfolio of businesses, strategic partnerships, and acquisitions, Callan JMB is building a broader platform spanning healthcare and pharmaceutical logistics, domestic manufacturing, transformer and critical electrical-equipment manufacturing, critical-infrastructure services, and energy development. For more information, visit callanjmb.com.

Investor Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254

Media Contact
Arian Hopkins
ahopkins@callanjmb.com

About the Atlas Complex by Callan JMB

Atlas Complex by Callan JMB is a pharmaceutical, medical, and logistics campus located in Marion, Alabama. Designed to support U.S. pharmaceutical onshoring and strengthen domestic supply chains, the campus provides scalable infrastructure for pharmaceutical manufacturing, quality assurance and quality control (QA/QC), research collaboration, workforce development, cold chain logistics, and domestic distribution within a single integrated environment.

Atlas Complex Media Contact:
Arian Hopkins
ahopkins@callanjmb.com

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), today announced that updated clinical data from its ongoing Phase 2 CLOVER study (ClinicalTrials.gov Identifier: NCT06699836), evaluating leronlimab in combination with trifluridine and tipiracil (“TAS-102”) plus bevacizumab in patients with previously treated mCRC, will be presented at the ESMO Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.

  Details of the poster presentation are as follows:

  Abstract title:

Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study

  Presenter:

Benjamin Weinberg, M.D., Associate Professor at Georgetown University

  Date and Time:

Sunday, October 25, 2026, 12:00-12:45 p.m. CET (local time)

  Poster ID:

820P

  Location: Poster Area, Hall 5, IFEMA Madrid

“We are excited to present updated findings from the CLOVER study at ESMO and share additional clinical and translational insights from our metastatic colorectal cancer program,” said Jacob P. Lalezari, M.D., Chief Executive Officer of CytoDyn. “These data will contribute to our understanding of CCR5 biology in colorectal cancer and help inform the continued development of leronlimab in combination with established therapies for patients with difficult-to-treat disease.”

A copy of the poster will be made available on CytoDyn’s website under the Publications & Posters section, shortly after the presentation date.

About the European Society for Medical Oncology (ESMO) Congress 2026

The ESMO Congress 2026, taking place October 23–27, 2026, in Madrid, Spain, is a leading global oncology meeting bringing together clinicians, researchers, patient advocates, journalists and healthcare industry representatives from around the world. The Congress provides a global platform for advances in oncology research, clinical practice and patient care, featuring new scientific data, educational programming, networking opportunities and innovation across the oncology community. For more information, visit esmo.org.

About CytoDyn

CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.

For more information, please visit www.cytodyn.com and follow us on LinkedIn.

Note Regarding Forward-Looking Statements

This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.

Corporate Contact
CytoDyn Inc.
ir@cytodyn.com

Media Contacts
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com

Targets mid-single-digit organic sales growth and 300 basis points of margin expansion over the next five years

Introduces 2035 ambition to double sales and triple Adjusted EBITDA

Strategy designed to support high-single-digit to double-digit annual shareholder returns over time

OXNARD, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) — Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”), a world leader in sourcing, producing, and distributing fresh Hass avocados, today is hosting its 2026 Investor Day in New York City. Management is presenting the Company’s five-year growth strategy and its ambition to double sales and triple profit by 2035.

After more than four decades of building the global supply network, infrastructure and customer capabilities behind its category leadership, Mission is entering a new chapter focused on generating more growth, earnings and cash flow from its platform. The Company’s largest value-creation initiatives are already underway, including the integration of Calavo Growers, expansion of higher-margin Prepared Foods, and improved utilization of Mission’s asset base.

Management Comments

John Pawlowski, President and Chief Executive Officer of Mission, stated, “Mission was built to lead. Over more than 40 years, we built the modern avocado category and created a platform that would be difficult to replicate. Our next chapter is about fully leveraging that platform and compounding the value we deliver to shareholders by growing faster than our markets, expanding margins, converting more earnings into cash and deploying that cash with discipline.”

“Our growth opportunity is broad and compelling. U.S. avocado remains one of the most durable growth stories in food. International markets offer substantial consumption headroom. Prepared Foods extends our avocado leadership into a higher-margin, growing category, and mango gives us a capital-efficient path to develop the next fresh platform. With Calavo synergies and better utilization of the assets already in place, we believe Mission can become a larger, more productive and higher-return company.”

A Financial Framework Built to Compound

Mission’s five-year plan is built around four connected goals for long-term shareholder value creation:

  • Organic sales growth: Grow faster than the markets the Company serves, supporting mid-single-digit organic sales growth over the five-year period.
  • Margin expansion: Expand margins by approximately 300 basis points over five years through improved portfolio mix, Calavo synergies, SG&A leverage and greater asset utilization.
  • Cash conversion: Convert more than 90% of Adjusted Net Income into free cash flow over time.
  • Disciplined capital allocation: Invest in the core business, reduce net leverage (total debt less cash) below 1.5 times Adjusted EBITDA, pursue disciplined M&A and execute opportunistic share repurchases.

Together, these initiatives are expected to support high-single-digit organic Adjusted EBITDA growth over the five-year period. Combined with disciplined M&A and opportunistic share repurchases, the framework is designed to support high-single-digit to double-digit annual shareholder returns over time.

Calavo Integration Progressing

Mission has pooled supply, closed the Temecula operation and established its future-state U.S. distribution footprint. The Company is now advancing network and systems transitions, and will be followed by the integration of remaining operations, including Mexico packing and Prepared Foods.

As announced in its fiscal third quarter 2026 earnings release, Mission increased its annualized synergy target from at least $25 million to more than $30 million. The Company expects a small contribution in the fourth quarter of fiscal 2026 and continues to target the full annualized run rate within 18 months of closing.

Disciplined Capital Allocation

Mission’s capital-allocation priorities are to invest in the core business, reduce net leverage below 1.5 times Adjusted EBITDA, pursue M&A where strategic fit and returns are compelling, and repurchase shares opportunistically. The Company currently has a $100 million share-repurchase authorization, which provides meaningful flexibility.

Bryan Giles, Chief Financial Officer of Mission, stated, “Mission is entering a financially compelling stage, with the majority of the heavy investment required to build our platform behind us and the Calavo acquisition adding scale, new capabilities and a meaningful synergy opportunity.”

“Our five-year framework is designed to grow earnings faster than sales and convert more of those earnings into cash. That should give us greater capacity to reduce leverage, fund high-return growth and return capital when it creates attractive value for shareholders.”

Fiscal 2026 Outlook Reaffirmed

Mission is reaffirming its previously provided outlook for the second half and fourth quarter of fiscal 2026:

  • Second-half fiscal 2026 Adjusted EBITDA of $84 million to $88 million, including fourth-quarter Adjusted EBITDA of $52 million to $55 million; and
  • Mission Peru exportable volume of 120 million to 130 million pounds in the second half, including 67 million to 77 million pounds in the fourth quarter.

Webcast Information

The 2026 Investor Day will be webcast live beginning at 10:00 a.m. ET today. The webcast, along with the presentation materials, will be accessible in the News & Events section of the Company’s investor relations website at https://investors.missionproduce.com. A replay will be available on the same site following the event.

Non-GAAP Financial Measures

This press release contains the non-GAAP financial measures “Adjusted EBITDA,” “Adjusted Net Income” and “Free Cash Flow.” Management believes these measures provide useful information for analyzing the underlying business results. These measures are not in accordance with, nor are they a substitute for or superior to, the comparable financial measures by generally accepted accounting principles.

Adjusted EBITDA refers to net income before interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, other income (expense), and income (loss) from equity method investees, further adjusted by asset impairment and disposals, farming costs for nonproductive orchards (which represents land lease costs), recognition of deferred ERP costs, transaction advisory costs, and any special, non-recurring, or one-time items such as remeasurements or impairments, and any portion of these items attributable to the noncontrolling interest. Segment adjusted EBITDA refers to, with respect to the applicable segment, net income (loss), before interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, other income (expense), and income (loss) from equity method investees, further adjusted by asset impairment and disposals, farming costs for nonproductive orchards (which represents land lease costs), recognition of deferred ERP costs, transaction advisory and integration costs, amortization of inventory adjustments recognized from business combinations, and any special, non-recurring, or one-time items such as remeasurements or impairments, and any portion of these items attributable to the noncontrolling interest.

Adjusted Net Income refers to net income attributable to Mission Produce, before stock-based compensation expense, unrealized gain (loss) on derivative financial instruments, foreign currency gain (loss), farming costs for nonproductive orchards (which represents land lease costs), recognition of deferred ERP costs, transaction advisory and integration costs, amortization of inventory adjustments and intangible asset recognized from business combinations, further adjusted by any special, non-recurring, or one-time items such as remeasurement, impairment or discrete tax charges that are distortive to results, and tax effects of these items, if any, and the tax-effected impact of these non-GAAP adjustments attributable to noncontrolling interest, allocable to the noncontrolling owners based on their percentage of ownership interest.

Free cash flow refers to cash flow from operations minus capital expenditures.

We have not reconciled our forward-looking non-GAAP financial measures to the most directly comparable GAAP measures in reliance on the “unreasonable efforts” exception in Item 10(e)(1)(i)(B) of Regulation S-K. These measures include our fiscal 2026 Adjusted EBITDA outlook, our fiscal 2035 Adjusted EBITDA ambition, our Adjusted EBITDA growth target, our Free Cash Flow Conversion target and our Net Debt to Adjusted EBITDA target. We cannot provide these reconciliations without unreasonable efforts because we cannot predict with reasonable certainty the amount or timing of certain items. These items include stock-based compensation, unrealized gains and losses on derivative financial instruments, foreign currency gains and losses, asset impairments and disposals, transaction advisory and integration costs and income taxes. They are inherently uncertain, depend on factors outside our control and could be material, individually or in the aggregate, to our GAAP results.

About Mission Produce, Inc.

Mission Produce is a global leader in the worldwide fresh produce industry and the world’s premier supplier of fresh Hass avocados, serving retail, wholesale, and foodservice customers in more than 25 countries. Since 1983, Mission has been dedicated to sourcing, producing, and distributing avocados, building one of the most integrated and diversified avocado supply networks in the world. While avocados remain at the core of its business, Mission also markets and distributes mangos, tomatoes, papayas, value-added prepared foods, including guacamole, and grows blueberries as part of its diversified portfolio. The Company is vertically integrated and has sourcing capabilities across 20+ premium growing regions. With a global distribution network spanning North America, Europe, the United Kingdom, and China, Mission provides a reliable year-round supply of premium products and value-added services, including ripening, bagging, custom packing, and logistics management. For more information, visit www.missionproduce.com.

Forward-Looking Statements

Statements in this press release that are not historical in nature are forward-looking statements that, within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, involve known and unknown risks and uncertainties. Words such as “may”, “will”, “expect”, “intend”, “plan”, “believe”, “seek”, “could”, “estimate”, “judgment”, “targeting”, “should”, “anticipate”, “goal” and variations of these words and similar expressions, are also intended to identify forward-looking statements. The forward-looking statements in this press release address a variety of subjects, including statements about our anticipated future performance, anticipated synergies related our completed acquisition of Calavo, the anticipated future performance of Calavo, and our short-term and long-term assumptions, goals and targets. Many of these assumptions relate to matters that are beyond our control and changing rapidly. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurances that our expectations will be attained. Readers are cautioned that actual results could differ materially from those implied by such forward-looking statements due to a variety of factors, including: reliance on primarily one main product, limitations regarding the supply of fruit, either through purchasing or growing; ; the risks that the businesses of Mission Produce and Calavo will not be integrated successfully or that the integration will be more costly or difficult than expected; the risk that the cost savings and any other synergies from the completed acquisition of Calavo may not be fully realized or may take longer to realize than expected; the risk of underperformance of Calavo’s business; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect; the risk of adverse reactions or changes to business or employee relationships resulting from the completion of the acquisition of Calavo; fluctuations in the market price of fruit; increasing competition; risks associated with doing business internationally, including Mexican and Peruvian economic, political and/or societal conditions; inflationary pressures; establishment of sales channels and geographic markets; loss of one or more of our largest customers; general economic conditions or downturns; supply chain failures or disruptions; disruption to the supply of reliable and cost-effective transportation; failure to recruit or retain employees, poor employee relations, and/or ineffective organizational structure; inherent farming risks, including climate change; seasonality in operating results; failures associated with information technology infrastructure, system security and cyber risks; new and changing privacy laws and our compliance with such laws; food safety events and recalls; failure to comply with laws and regulations; changes to trade policy and/or export/import laws and regulations; risks from business acquisitions, if any; lack of or failure of infrastructure; material litigation or governmental inquiries/actions; failure to maintain or protect our brand; changes in tax rates or international tax legislation; risks associated with global conflicts; inability to accurately forecast future performance; the viability of an active, liquid, and orderly market for our common stock; volatility in the trading price of our common stock; concentration of control in our executive officers, and directors over matters submitted to stockholders for approval; limited sources of capital appreciation; significant costs associated with being a public company and the allocation of significant management resources thereto; reliance on analyst reports; failure to maintain proper and effective internal control over financial reporting; restrictions on takeover attempts in our charter documents and under Delaware law; the selection of Delaware as the exclusive forum for substantially all disputes between us and our stockholders; risks related to restrictive covenants under our credit facility, which could affect our flexibility to fund ongoing operations, uses of capital and strategic initiatives, and, if we are unable to maintain compliance with such covenants, lead to significant challenges in meeting our liquidity requirements and acceleration of our debt; and other risks and factors discussed from time to time in our Annual and Quarterly Reports on Forms 10-K and 10-Q, the “Risk Factors” in our Proxy Statement/Prospectus dated March 20, 2026 (the “Proxy Statement/Prospectus”), and in our other filings with the Securities and Exchange Commission. You can obtain copies of our SEC filings on the SEC’s website at www.sec.gov. The forward-looking statements contained in this press release are made as of the date hereof and the Corporation does not intend to, nor does it assume any obligation to, update or supplement any forward-looking statements after the date hereof to reflect actual results or future events or circumstances.

Contacts

Investor Relations
Andrew Pearson
Vice President Investor Relations and Strategy
Mission Produce, Inc.
apearson@missionproduce.com

Media
Jenna Aguilera
Director of Communications
Mission Produce, Inc.
press@missionproduce.com

HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc.TM (NASDAQ: SKWD) (“Skyward Group” or “the Company”) expects to issue its third quarter 2026 earnings results, inclusive of Apollo Group Holdings Ltd., after the market closes on Thursday, November 5 which will be available on the Company website at investors.skywardinsurance.com/ under Quarterly Results.

Skyward Group will host its earnings call to review the third quarter 2026 financial results on Friday, November 6 at 10:00 a.m. EST.

Investors may access the live audio webcast via the link on the Company’s investor site at investors.skywardinsurance.com/ under Events & Presentations. Additionally, investors can access the earnings call via conference call by registering via the conference link. Users will receive dial-in information and a unique PIN to join the call upon registering.

A webcast replay will be available two hours following the call in the same location on the Company’s investor website.

About Skyward Group

Skyward Group is the holding company brand for its U.S. and Lloyds businesses, Skyward Specialty Insurance Group, Inc.® and Apollo, respectively, delivering a comprehensive suite of specialized insurance solutions across global specialty property and casualty markets. Focused on the specialty industry’s most niche, complex risks of today and the emerging challenges of tomorrow, Skyward Group leverages the forward-looking insight and disciplined execution of each organization to drive sustainable growth and long-term value for its shareholders, distribution partners, and other stakeholders.

For more information about Skyward Group, Skyward Specialty, and Apollo, please visit skywardgroup.com

For investor relations information contact:

Jordan Arnold
JArnold@skywardinsurance.com
346.215.0250

Medical Advisory Board represents another milestone in Nuwellis’ broader pediatric strategy, alongside proposed Aquadex SmartFlow® label expansion seeking to extend to pediatric patients weighing 5 kilograms or more

MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company’s next-generation pediatric continuous renal replacement therapy (CRRT) platform. Vivian is under development for children as small as 2.5kg and it incorporates multiple fluid management therapies in one platform.

“Vivian is being purpose-built around the unique clinical and operational needs of pediatric patients and the clinicians who care for them,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “Direct provider and nurse input at this critical stage provides the opportunity to validate the progress we have made and ensure that the voice of the customer continues to shape the system as we move forward. We believe the advisory board is an important development milestone within our pediatric strategy and reflects our commitment to building solutions that address unmet needs across the continuum of care.”

The meeting assembles approximately a dozen pediatric providers, nurses, and clinical advisors representing 11 nationally recognized pediatric institutions across the U.S. for an immersive, hands-on evaluation of the latest Vivian System. The advisory board marks the Company’s first dedicated Vivian Medical & Nursing Advisory Board in several years and represents an important step as Nuwellis advances the system through its next phase of product development.

Feedback from the Medical & Nursing Advisory Board is expected to help Nuwellis validate design decisions, identify unmet clinical and workflow needs, and prioritize future system enhancements. Nuwellis will incorporate insights gathered during the meeting into development priorities and refinements intended to guide Vivian toward its next major program milestones.

The Vivian Medical & Nursing Advisory Board is part of Nuwellis’ broader strategy to strengthen its position in pediatric fluid management and renal support. The Company has built a growing presence in pediatric hospitals using its Aquadex SmartFlow ultrafiltration system and is working through regulatory procedures to is seeking to expand the Aquadex indication to pediatric patients weighing 5 kilograms or more, compared with the system’s current 20-kilogram minimum labeled patient weight.

Together with continued development of Vivian, these initiatives represent a multi-pronged pediatric strategy spanning near-term expansion of Aquadex and longer-term development of a purpose-built pediatric CRRT platform.

About Aquadex
The Aquadex SmartFlow System is currently indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026.

Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial
Session Type: Late-Breaking Science (Oral Presentation)
Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction
Session Date and Time: Monday, November 9, 2026, 8:00 a.m. CST

The accepted abstract titles are available online on the AHA website. The data in the abstract and presentation are embargoed until the date and time of presentation. A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.

About In Vivo Liver Editing Programs

CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and its novel, proprietary SyNTase™ editing technology. The Company’s in vivo portfolio includes three cardiovascular programs: CTX310, targeting angiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia; CTX340™, targeting angiotensinogen (AGT), in development for refractory hypertension; and CTX321™, targeting LPA, in development for patients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company’s disclosed development candidates also include CTX460™, targeting SERPINA1 using SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency (AATD).

About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

CRISPR THERAPEUTICS® standard character mark and design logo, CTX310®, CTX321™, CTX340™, CTX460™ and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners. 

CRISPR Therapeutics Forward-Looking Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described oral presentation and any associated abstract; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in CRISPR Therapeutics most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact:
+1-617-307-7503
ir@crisprtx.com

Media Contact:
+1-617-315-4493
media@crisprtx.com

SciTec’s enhanced data fusion system enables warfighters to improve detection, tracking, and characterization of unmanned aerial threats

Firefly's SciTec Data Fusion System

*SciTec fused sensor data and mission visualizations supporting the U.S. Air Force’s Cloud‑Based Command and Control (CBC2) system and its newly expanded counter UAS integration

BOULDER, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) — SciTec, a Firefly Aerospace company, today announced an extension to its Cloud-Based Command and Control (CBC2) contract with the U.S. Department of the Air Force Command, Control, Communications, and Battle Management to integrate a new class of counter unmanned aerial system (CUAS) sensor feeds for the Advanced Battle Management System. The extension adds $1.5 million, bringing the total contract value to $31 million, and expands SciTec’s ongoing efforts to deliver the operational data fusion system that enhances command-and-control warfighting capabilities for mission partners.

Under this contract expansion, SciTec will expand its current data fusion system by adding additional approved counter-UAS sensor data sources. This expanded data layer supports improved situational awareness and decision-making for mission partners.

“This expansion underscores the critical role SciTec’s data fusion system plays in the Cloud-Based Command and Control ecosystem,” said David Simenc, SciTec’s President. “As new mission needs arise, our scalable architecture is already designed to rapidly integrate additional sensors and data types to strengthen warfighter decision making.”

CBC2 remains a central component of the Department of the Air Force Battle Network and supports the Combined Joint All Domain Command and Control vision. By continuously integrating new data sources and tools into the CBC2 system, SciTec and the Air Force are accelerating the pace at which modern battle management capabilities can be delivered to the operational edge.

About SciTec
SciTec, a wholly owned subsidiary of Firefly Aerospace, is a leader in advanced defense technologies. Headquartered in Princeton, N.J., SciTec has more than four decades of experience supporting high-stakes national security missions with AI-enabled defense software and cloud-based, on-premise, and edge processing capabilities. SciTec’s industry-leading software and big data processing capabilities are proven in operations for missile warning and defense; intelligence, surveillance and reconnaissance; space domain awareness; remote sensing and analysis; and autonomous command and control. For more information, visit www.scitec.com.

About Firefly Aerospace
Firefly Aerospace is a space and defense technology company on a mission to reliably and repeatedly launch, land, and operate space systems from Earth to the Moon and beyond. As the partner of choice for responsive space missions, Firefly is the first commercial company to launch a satellite to orbit with approximately 24-hour notice and the first to achieve a successful landing on the Moon. Established in 2017, Firefly’s engineering, manufacturing, and test facilities are co-located in central Texas to enable rapid innovation and vertical integration for the company’s small- to medium-lift launch vehicles, lunar landers, and orbital vehicles. For more information, visit www.fireflyspace.com.

Forward-Looking Statements
This press release contains “forward-looking statements” including, but not limited to, statements regarding total contract value, SciTec’s plans and capabilities, pace of delivery of modern battle management capabilities, and statements of SciTec’s leadership team. These and other statements regarding Firefly’s (and its subsidiary SciTec’s) future expectations, beliefs, plans, objectives, assumptions, or performance that are not historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “modernize,” “may,” “will,” “expands,” “expects,” “plans,” “anticipates,” “could,” “would,” “target,” “intends,” “support,” and “believes.” There may also be negative words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Not all forward-looking statements contain such identifying words. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates, or expectations will be achieved.

Various risks that could cause actual results to differ from those expressed by the forward-looking statements included in this press release include, but are not limited to: disruptions in U.S. government operations, funding, and budgetary or procurement priorities; the fact that U.S. government contracts are generally not fully funded at inception, may be undefinitized, and may be reduced, modified, or terminated, which could prevent us from realizing our backlog; our dependence on a limited number of customers; our inability to comply with our contractual obligations or to meet the eligibility requirements and security-clearance certifications for government contracts; the limitations on disclosure arising from classified contracts; the extensive regulation of defense-industry contracting; a failure of our information technology systems or security protections; our failure to realize the expected benefits of the SciTec acquisition; the fluctuation of our operating results; adverse publicity stemming from any incident involving us, our competitors, or our customers; the failure to adequately protect our proprietary intellectual property rights; and other risk factors set forth in Firefly’s filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. These statements are based on management’s current expectations, assumptions, and beliefs concerning future developments, which are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. We cannot assure you that the events reflected in the forward-looking statements will occur; actual events could differ materially from those described in the forward-looking statements. We undertake no intent or obligation to publicly update or revise any of the estimates and other forward-looking statements made in this announcement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contacts
press@scitec.com
press@fireflyspace.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9fce9fb5-e1e9-43b0-a4ab-45a61b2aa9f1

Trailer is designed to support automated multi-drone spraying and seeding, with automated battery recharging, launch and landing platform, with future adaptations planned for surveying and inspections

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its ZenaDrone subsidiary has begun building a mobile agricultural drone operations trailer and will begin testing it in the coming months. The trailer is designed to transport and automate precision agriculture Drone as a Service jobs including for drone swarm operations. It is being configured to work with the IQ Octo drone, to complete jobs with minimal human intervention, improving speed and job capacity, and will be adapted to work with other DaaS applications such as surveys and inspection jobs in the future. The IQ Octo is ZenaDrone’s medium-sized, eight-motor autonomous drone currently at the prototype testing stage, built for precision spraying and seeding. Battery powered, it is designed for roughly 20 to 25 minutes of flight per charge and a payload of up to 25 kilograms of liquid or seed, applying fertilizers, crop-protection products, and seed along programmed flight paths.

“Our customers want more acres covered, jobs completed faster, and lower service costs. Developing a mobile operations trailer to support multiple drones, with spraying, seeding, and spreading capabilities and automated battery recharging, is aimed squarely at those needs,” said Shaun Passley, Ph.D., ZenaTech CEO. “We are starting development and testing in precision agriculture, with the goal of extending this approach across our Drone as a Service applications. For ZenaTech’s DaaS business, the opportunity is to serve more customers with each crew and drone fleet, supporting stronger margins and a more scalable service business.”

The trailer is designed as a customizable mobile hub that transports drones and supports field operations, including battery charging, payload replenishment, and autonomous takeoff and landing. Built for compact and road-worthy field operations, it has a retractable top cover and panels for fast drone set up and launch directly from the trailer. It is built to support drone swarms of up to five aircrafts working across precision agriculture jobs, beginning with IQ Octo spraying, seeding, and spreading operations, and can later be adapted for surveying and inspection applications. The trailer is currently in the prototype build-and-test stage at the Company’s facility in Mesa, Arizona where it is expected to be produced.

A mobile operations trailer supporting four to five drones is designed to deliver faster job completion, less downtime, lower operating costs, and greater daily capacity. By bringing spraying, seeding, and spreading supplies directly to the job site with automated refilling, and by recharging batteries without manual intervention, the trailer is designed to keep fleets flying with fewer interruptions and less hands-on servicing. The goal is quicker turnaround and planned lower costs for customers, enabling DaaS operators to cover more acres, complete more jobs, and improve margins from the same fleet.

Drone as a Service (DaaS) is ZenaTech’s model for delivering drone-based automation of legacy or manual jobs, data, and analytics as a recurring service rather than selling drone hardware outright. It is designed to give customers across agriculture, land surveying and construction, industrial inspections and maintenance, power washing of buildings, and other industries access to automated drone capabilities without owning or operating a fleet, while building a scalable, recurring-revenue business for ZenaTech.

The Company will provide further updates as it reaches additional development and testing milestones for the mobile agricultural drone operations trailer.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, the IQ Aqua, for underwater applications, and the IQ Octo for precision agriculture. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors and Media:
Linda Montgomery
ZenaTech
312-241-1415

Investors:
Michael Mason
CORE IR
investors@zenatech.com

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Nano, IQ Square, IQ Quad, IQ Aqua, IQ Octo, IQ Glider, IQ Sphere, ZenaDrone 2000, Interceptor P-1; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.